ANAHEIM, Calif., June 16, 2017— Gala Global, Inc. (GLAG), a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotechnology industry, has named Dr. Maqsood Rehman as the company’s Chief Operating Officer (COO).
“We welcome Dr. Rehman as he brings with him a diverse background of working for large public and private companies in the field of genetics and the commercialization of genetically modified crops for a wide variety of uses,” said Gala Global CEO Timothy Madden.
Dr. Rehman will be leading Gala Global’s development team working to commercialize digital plant cloning incubators from Controlled Environment Genomics, Inc. (CEG), an Akron, Ohio-based genomics company recently acquired by Gala Global that specializes in digital plant gene sequencing, editing and cloning technologies.
CEG’s state-of-the-art genomics technology makes possible digital genome sequencing and plant cloning systems. These enable developers to digitally sequence the genomes of the most desirable plant varieties based on flavor and nutrition. As a result, the very best plant traits can be used to improve the most sought- after commercial varieties with characteristics like maximized yield and quality conducive to increased consumer demand and improved production profitability.
Dr. Rehman will also be working with GenoBreeding Inc., a division of Greengro Technologies, Inc. (OTC: GRNH), Anaheim, Calif. GenoBreeding was formed in early 2017 to direct a Greengro initiative intended to bring to the plants and herbs markets cutting-edge plant varieties through the application of modern plant breeding technologies.
Gala’s business strategy is to develop breeding tools like molecular markers to enable productive plant breeding decisions and processes that achieve top-tier plant performance in a sustainable manner.
About Gala Global Inc.
Gala Global, Inc., Anaheim, Calif., is a publicly-traded startup development company specializing in equity investments, debt financing and mergers and acquisitions (M&A) in the biotech industry. Gala Global’s professional services group provides operational services and technologies that drive efficiencies in the market. Gala Global has industry-leading expertise helping companies make the most of their potential in an emerging market. Gala Global website: www.galaglobalinc.com.
Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Timothy J. Madden, CEO
Gala Global, Inc.